EHAB Logo

Enhabit, Inc. (EHAB) 

NYSE
Market Cap
$394.47M
Sector
Healthcare
Industry
Medical—Care Facilities
Rank in Sector
173 of 776
Rank in Industry
7 of 39

Largest Insider Buys in Sector

EHAB Stock Price History Chart

EHAB Stock Performance

About Enhabit, Inc.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific …

Insider Activity of Enhabit, Inc.

Over the last 12 months, insiders at Enhabit, Inc. have bought $282,400 and sold $5,586 worth of Enhabit, Inc. stock.

On average, over the past 5 years, insiders at Enhabit, Inc. have bought $591,111 and sold $5,586 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Bolton Jeffrey (director) — $264,400. Hoeflinger Erin (director) — $18,000.

The last purchase of 5,000 shares for transaction amount of $40,050 was made by Bolton Jeffrey (director) on 2024‑08‑22.

List of Insider Buy and Sell Transactions, Enhabit, Inc.

2024-08-22Purchasedirector
5,000
0.0099%
$8.01$40,050-4.86%
2024-08-09Purchasedirector
5,000
0.0098%
$8.29$41,450-6.68%
2024-08-08Purchasedirector
2,000
0.004%
$8.60$17,200-7.28%
2024-05-17Purchasedirector
10,000
0.0193%
$8.33$83,300+1.09%
2024-05-14Purchasedirector
2,000
0.004%
$9.00$18,000-7.85%
2024-05-10Purchasedirector
10,000
0.0197%
$8.24$82,400+0.60%
2024-03-01SaleEVP Clinical Excel. & Strategy
634
0.0013%
$8.81$5,586+1.82%
2023-05-26Purchasedirector
2,000
0.004%
$11.61$23,220-7.53%
2023-05-22Purchasedirector
10,000
0.0198%
$11.98$119,800-12.08%
2023-05-18PurchaseEVP Clinical Excel. & Strategy
10,000
0.02%
$11.99$119,900-10.68%
2023-05-18Purchasedirector
2,100
0.0042%
$11.82$24,822-10.68%
2023-05-17Purchasedirector
2,000
0.0039%
$11.80$23,600-10.81%
2022-11-18Purchasedirector
1,000
0.002%
$12.69$12,690-0.93%
2022-11-09Purchasedirector
2,000
0.004%
$12.75$25,500+0.08%
2022-11-08Purchasedirector
2,000
0.004%
$12.89$25,780-1.77%
2022-11-08Purchasedirector
426
0.0009%
$13.57$5,781-1.77%
2022-11-07Purchasedirector
8,300
0.0163%
$12.69$105,327-2.15%
2022-11-04Purchasedirector
1,700
0.0034%
$12.58$21,386+1.19%
2022-08-31Purchase
1,550
0.003%
$15.99$24,785-19.37%
2022-08-18Purchase
970
0.0019%
$13.90$13,483-4.05%

Insider Historical Profitability

<0.0001%
Bolton Jeffreydirector
78877
0.1569%
$7.85110<0.0001%
Langham Ronald Leroy JREVP Clinical Excel. & Strategy
57164
0.1137%
$7.8511<0.0001%
Hoeflinger Erindirector
30399
0.0605%
$7.8530<0.0001%
Jacobsmeyer Barbara AnnPresident and CEO
238442
0.4742%
$7.8510+3.36%
SHAW L EDWARD JRdirector
38989
0.0775%
$7.8520<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$93.2M15.958M-1.17%-$1.1M<0.01
Deerfield Management$58.22M9.965M0%+$00.14
The Vanguard Group$53.95M9.234.63M-18.85%-$12.53M<0.01
AREX Capital Management, LP$28.12M4.812.41M-0.03%-$9,424.8531.49
State Street$23.2M3.971.99M-0.82%-$190,920.20<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.